Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy

Critical Reviews in Oncology/Hematology

Volumn 47, Issue 1, 2003, Pages 1-11

  Van Belle, Simon Jean Pierre ^a   Cocquyt, Véronique ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Anaemia; Cancer; Cellular hypoxia; Chemotherapy; Haemoglobin levels; Leukaemia; Lymphoma; Predictive factor; Prognostic factor; Quality of life

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; IFOSFAMIDE; IRINOTECAN; PACLITAXEL;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CELL HYPOXIA; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; CYTOLOGY; DRUG BLOOD LEVEL; ERYTHROCYTE; HEAD CANCER; HEMOGLOBIN DETERMINATION; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MACROGLOBULINEMIA; METABOLISM; METASTASIS; MULTIMODALITY CANCER THERAPY; MUTATION; NECK CANCER; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PROGNOSIS; PROSTATE CANCER; SOLID TUMOR; SURVIVAL RATE; TREATMENT OUTCOME; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0038350531     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00093-3     Document Type: Conference Paper

References (53)

1. Mercadantes S., Gebbia V., Marrazzo A. Anaemia in cancer: pathophysiology and treatment. Cancer Treat. Rev. 26:2000;303-311.
2. Bron D., Meuleman N., Mascaux C. Biological basis of anemia. Semin. Oncol. 28:2001;1-6.
3. Ludwig H. Epoetin in cancer-related anaemia. Nephrol. Dial. Transplant. 14:1999;85-92.
4. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19:2001;2865-2874.
5. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer. 91:2001;2214-2221.
6. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
7. Hockel M., Vaupel P. Biological consequences of tumor hypoxia. Semin. Oncol. 28:2001;36-41.
8. Reiher F.K., Ivanovich M., Huang H., Smith N.D., Bouck N.P., Campbell S.C. The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer. J. Urol. 165:2001;2075-2081.
9. Reynolds T.Y., Rockwell S., Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res. 56:1996;5754-5757.
10. Vaupel P., Thews O., Kelleher D.K., Hoeckel M. Oxygenation of human tumors: the Mainz experience. Strahlenther. Onkol. 174:(Suppl 4):1998;6-12.
11. Young S.D., Marshall R.S., Hill R.P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. USA. 85:1988;9533-9537.
12. Moullet I., Salles G., Ketterer N., et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann. Oncol. 9:1988;1109-1115.
13. Federico M., Vitola U., Zinzani P., et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood. 95:2000;783-789.
14. Samaha H., Dumontet C., Ketterer N., et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia. 12:1998;1281-1287.
15. Hasenclever D., Diehl V. A prognostic score for advanced Hodkin's disease. N. Engl. J. Med. 339:1998;1506-1514.
16. Landman-Parker J., Pacquement H., Leblanc T., et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy - results of the French Society of Pediatric Oncology Study MDH90. J. Clin. Oncol. 18:2000;1500-1507.
17. Liao Z., Ha C.S., Fuller L.M., et al. Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 41:1998;1047-1056.
18. Kern W., Schoch C., Haferlach T., et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia. 14:2000;226-231.
19. Metze K., Lobo A.M., Lorand-Metze I. Nucleolus organizer regions (AgNORs) and total tumor mass are independent prognostic parameters for treatment-free period in chronic lymphocytic leukemia. Int. J. Cancer. 89:2000;440-443.
20. Keating M.J., Smith T.L., Lerner S., et al. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leukemia Lymphoma. 37:2000;71-85.
21. Morel P., Monconduit M., Jacomy D., et al. Prognostic factors in Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 96:2000;852-858.
22. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J. Clin. Oncol. 9:1991;1618-1626.
23. Wilhelm R., Kovacs G., Heinrichsohn D., Galalae R., Kimmig B. Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin level. Strahlenther. Onkol. 174:1998;128-132.
24. Ohlhauser C., Bulzebruck H., Ebert W., Drings P., Wannenmacher M. Prognostic factors for survival in inoperable non-small-cell lung cancer: a multivariate regression analysis of 456 patients with radiation therapy. Onkologie. 20:1997;126-131.
25. Ylisirnio S., Sassi M.L., Risteli J., et al. Serum type I collagen degradation markers, ICTP and CrossLaps are factors for poor survival in lung cancer. Anticancer Res. 19:1999;5577-5581.
26. Obermair A., Petru E., Windbichler G., et al. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol. Rep. 7:2000;639-644.
27. Eisenhauer E.A., Vermorken J.B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8:1997;963-968.
28. Girinski T., Pejovic-Lenfant M.H., Bourhis J., et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int. J. Radiat. Oncol. Biol. Phys. 16:1988;37-42.
29. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 86:1999;1528-1536.
30. Hockel M., Schlenger K., Hockel S., Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Int. J. Gynecol. Cancer. 9:1999;121-122.
31. Masuda H., Kurita Y., Suzuki A., Kanbayashi T., Suzuki K., Fujita K. Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases. Int. J. Urol. 4:1997;247-253.
32. Masuda H., Kurita Y., Fukuta K., Mugiya S., Suzuki K., Fujita K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int. J. Urol. 5:1998;418-422.
33. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17:1999;2530-2540.
34. Sengelov L., Kamby C., Schou G., et al. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer. 74:1994;123-133.
35. Sengelov L., Kamby C., Geersten P., et al. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother. Pharmacol. 46:2000;357-364.
36. Matzkin H., Perito P.E., Soloway M.S. Prognostic factors in metastatic prostate cancer. Cancer. 72:1993;3788-3792.
37. Johansson J.E., Sigurdsson T., Holmberg L., et al. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. Cancer. 70:1992;1556-1563.
38. Vollmer R.T., Kantoff P.W., Dawson N.A., et al. A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. Clin. Cancer Res. 5:1999;831-837.
39. Lee W.R., Berkey B., Marcial V. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;1069-1075.
40. Wagner W., Hermann R., Hartlapp J., et al. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther. Onkol. 176:2000;73-80.
41. Vaupel P., Thews O., Kelleher D.K., Hoeckel M. Oxygenation of human tumors: the Mainz experience. Strahlenther. Onkol. 174:(Suppl 4):1998;6-12.
42. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
43. Dunst J., Pigorsch S., Hansgen G., Hintner I., Lautenschlager C., Becker A. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther. Onkol. 175:1999;93-96.
44. Gatenby R.A., Kessler H.B., Rosenblum J.S., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14:1988;831-838.
45. Graham C.H., Forsdike J., Fitzgerald C.J., Macdonald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer. 80:1999;617-623.
46. Hasan N.M., Adams G.E., Joiner M.C., Marshall J.F., Hart I.R. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br. J. Cancer. 77:1998;1799-1805.
47. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
48. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
49. Teicher B.A., Dupuis N.P., Emi Y., Ikebe M., Kakeji Y., Menon K. Increased efficacy of chemo- and radio-therapy by a hemoglobin solution in the 9L gliosarcoma. In Vivo. 9:1995;11-18.
50. Teicher B.A., Ara G., Herbst R., Takeuchi H., Keyes S., Northey D. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. In Vivo. 11:1997;301-311.
51. Teicher B.A., Holden S.A., Menon K., Hopkins R.E., Gawry M.S. Effect of hemoglobin solution on the response of intracranial and subcutaneous 9L tumors to antitumor alkylating agents. Cancer Chemother. Pharmacol. 33:1993;57-62.
52. Silver D.F., Piver M.S. Effects of recombinant human erythropoetin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol. Oncol. 73:1999;280-284.
53. Schrijvers D., Highley M., De Bruyn E., Van Oosterom A.T., Vermorken J.B. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs. 10:1999;147-153.